Last reviewed · How we verify
Lactic acid (Dermacyd Femina)
Lactic acid (Dermacyd Femina) is a Vaginal acidifying agent Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Vaginal hygiene and prevention of vaginal infections, Treatment of vulvovaginal candidiasis, Maintenance of normal vaginal microflora.
Lactic acid maintains vaginal pH and creates an acidic environment that inhibits the growth of pathogenic bacteria and fungi.
Lactic acid maintains vaginal pH and creates an acidic environment that inhibits the growth of pathogenic bacteria and fungi. Used for Vaginal hygiene and prevention of vaginal infections, Treatment of vulvovaginal candidiasis, Maintenance of normal vaginal microflora.
At a glance
| Generic name | Lactic acid (Dermacyd Femina) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Vaginal acidifying agent |
| Modality | Small molecule |
| Therapeutic area | Gynecology / Women's Health |
| Phase | Phase 3 |
Mechanism of action
Lactic acid is a naturally occurring organic acid that restores and maintains the acidic pH of the vaginal microenvironment (pH 3.8–4.5). By lowering pH, it suppresses the growth of opportunistic pathogens such as Candida species and gram-negative bacteria while promoting the growth of beneficial lactobacilli. This mechanism helps prevent and treat vaginal infections and maintain normal vaginal flora.
Approved indications
- Vaginal hygiene and prevention of vaginal infections
- Treatment of vulvovaginal candidiasis
- Maintenance of normal vaginal microflora
Common side effects
- Local irritation or burning
- Mild discomfort
Key clinical trials
- Dermacyd in Odor Reducing. (PHASE3)
- Dermacyd Femina (Lactic Acid) - Photo Dermatological Evaluation of the Irritation and Sensitivity Potential. (PHASE3)
- Dermacyd Femina Delicata (Lactic Acid)- Photo Dermatological Evaluation of the Irritation and Sensitivity Potential (PHASE3)
- Dermacyd Femina Pocket BR (Lactic Acid)- Acceptability. (PHASE3)
- Dermacyd Femina (Lactic Acid) Pocket BR - Photo Evaluation (PHASE3)
- Dermacyd Femina (Lactic Acid) Pocket BR - Compatibility (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactic acid (Dermacyd Femina) CI brief — competitive landscape report
- Lactic acid (Dermacyd Femina) updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Lactic acid (Dermacyd Femina)
What is Lactic acid (Dermacyd Femina)?
How does Lactic acid (Dermacyd Femina) work?
What is Lactic acid (Dermacyd Femina) used for?
Who makes Lactic acid (Dermacyd Femina)?
What drug class is Lactic acid (Dermacyd Femina) in?
What development phase is Lactic acid (Dermacyd Femina) in?
What are the side effects of Lactic acid (Dermacyd Femina)?
Related
- Drug class: All Vaginal acidifying agent drugs
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Gynecology / Women's Health
- Indication: Drugs for Vaginal hygiene and prevention of vaginal infections
- Indication: Drugs for Treatment of vulvovaginal candidiasis
- Indication: Drugs for Maintenance of normal vaginal microflora
- Compare: Lactic acid (Dermacyd Femina) vs similar drugs
- Pricing: Lactic acid (Dermacyd Femina) cost, discount & access